Wednesday, August 19, 2026
Moderna-Merck melanoma vaccine hits Phase 3 goals, shares surge
Merck and Moderna said August 19 that the Phase 3 INTerpath-001 trial of intismeran autogene (mRNA-4157) plus KEYTRUDA met both its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival in 1,137 patients with completely resected stage IIB-IV melanoma, the first positive Phase 3 result ever for an individualized mRNA neoantigen cancer therapy. Moderna shares surged as much as 90%+ intraday and Merck rose about 7-11%, and the companies said they plan to file for regulatory approval within months.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- FDA approves Moderna's mFlusiva, the first mRNA flu vaccineMonday, August 17, 2026
- Moderna opens trial of combined RSV/hMPV shot for older adultsSaturday, August 15, 2026
- FDA approves Moderna's mFlusiva, its first standalone flu shotThursday, August 6, 2026
- Moderna's norovirus vaccine misses Phase 3 interim efficacy barSaturday, August 1, 2026